Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.61 |
| ▸ | VEGFA | P15692 | 5/20 | 0.46 |
| ▸ | FLT1 | P17948 | 5/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.46 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.46 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.46 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.46 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150551 | 0.98 | EGLN1 (0.61) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL14150385 | 0.98 | EGLN1 (0.61) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL14150645 | 0.87 | EGLN1 (0.65) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL14150552 | 0.87 | EGLN1 (0.65) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL14150387 | 0.87 | EGLN1 (0.65) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL14165954 | 0.86 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL14166081 | 0.86 | EGLN1 (0.64) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933490 | 0.82 | EGLN1 (0.65) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3485365 | 0.81 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3485380 | 0.81 | EGLN1 (0.64) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865748-B2 | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer | AKEBIA THERAPEUTICS INC. (US) | 2014-10-21 | — | — | US | claimed |
| US-20120316204-A1 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | AKEBIA THERAPEUTICS INC. (US) | 2012-12-13 | — | — | US | claimed |
| US-8865748-B2 | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer | AKEBIA THERAPEUTICS INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120329836-A1 | METHODS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | THE OHIO STATE UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120316204-A1 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | AKEBIA THERAPEUTICS INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316204-A1 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | HIF1A, HIF1AN, EGLN2 | EGLN1 5/4885VEGFA 418/4885FLT1 1426/4885 |
| US-20120329836-A1 | METHODS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | HIF1A, HIF1AN, EGLN2 | EGLN1 6/4885VEGFA 353/4885FLT1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.